Riferimento:
Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):347-51.
Autori:
Bodei L1, Pepe G, Paganelli G.
Fonte:
Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):347-51.
Anno:
2010
Azione:
Gli analoghi radioattivi della somatostatina 90Y-DOTATOC e 177Lu-DOTATATE sono in grado di fornire alte dosi al recettore tumorale della somatostatina SST2 e basse dosi agli organi normali.
Target:
90Y-DOTATOC-177Lu-DOTATATE/tumori neuroendocrini.
ABSTRACT
BACKGROUND::
Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs.:
RESULTS AND CONCLUSIONS:
Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.
Sostanze: